Home/Pipeline/Next-Generation PI3Kα Pan-Mutant Selective Inhibitor

Next-Generation PI3Kα Pan-Mutant Selective Inhibitor

Breast Cancer

Phase 1/2Active

Key Facts

Indication

Breast Cancer

Phase

Phase 1/2

Status

Active

Company

OnKure Therapeutics, OnKure Therapeutics

About OnKure Therapeutics

OnKure Therapeutics is a U.S.-based, publicly traded biotech (OKUR) focused on discovering and developing precision medicines for cancer. The company's strategy centers on building a broad pipeline of tumor-agnostic, potentially best-in-class therapies, leveraging a leadership team with a proven track record. A key recent achievement is an oversubscribed $150 million private placement in March 2026 to advance its next-generation PI3Kα inhibitor candidates in breast cancer and vascular anomalies, providing significant capital to propel its lead programs forward.

View full company profile

About OnKure Therapeutics

View full company profile

Therapeutic Areas

Oncology Vascular Anomalies

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
GCT-007	Global Cancer Technology	Research	Active
NDES	Continuity Biosciences	Pre-clinical	Active